Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Sarepta Therapeutics Stock Performance
NASDAQ SRPT opened at $126.79 on Tuesday. The firm has a market cap of $12.11 billion, a P/E ratio of 101.43 and a beta of 0.77. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company's 50 day moving average is $123.30 and its 200-day moving average is $131.55. Sarepta Therapeutics, Inc. has a 12-month low of $89.92 and a 12-month high of $173.25.
Institutional Investors Weigh In On Sarepta Therapeutics
AI breakthrough about to upend industry
From Porter & Company | Ad
Everyone is talking about AI right now.
The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI.
But here’s the thing.
I urge you to watch it now.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its holdings in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after acquiring an additional 665,087 shares during the period. Erste Asset Management GmbH bought a new position in Sarepta Therapeutics in the 3rd quarter worth about $79,425,000. Janus Henderson Group PLC grew its holdings in Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after buying an additional 543,143 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Sarepta Therapeutics by 693.7% during the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company's stock valued at $57,356,000 after buying an additional 317,277 shares during the period. Finally, Soros Fund Management LLC purchased a new stake in shares of Sarepta Therapeutics in the third quarter worth about $25,800,000. Institutional investors own 86.68% of the company's stock.
Analyst Ratings Changes
A number of research firms have recently weighed in on SRPT. Cantor Fitzgerald upgraded Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and raised their target price for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Guggenheim raised their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Raymond James reiterated an "outperform" rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Robert W. Baird dropped their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research report on Thursday, November 7th. Finally, HC Wainwright reduced their price objective on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating for the company in a research report on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $178.71.
Read Our Latest Research Report on SRPT
Sarepta Therapeutics Company Profile
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
